Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Snbioscience Inc. is active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action currently under review. This matter is assigned to 1 distinct art unit, which indicates a focused technical scope for the company's current patent activities. Practitioners should prioritize understanding the specific examination standards and technical precedents of this 1 distinct art unit to navigate the prosecution effectively. The concentration of the portfolio within 1 distinct art unit allows for a highly targeted legal strategy that addresses the specific requirements of that technical group.
The prosecution of this portfolio is handled by 1 distinct examiner, WANG, CHANG YU, who is also the busiest examiner with 1 pending office action. Because WANG, CHANG YU is the only official involved in the company's current pending matters, the success of the portfolio depends on a productive relationship with this individual. Practitioners should carefully review the past decisions and preferences of WANG, CHANG YU to optimize their response to the 1 pending office action. This concentrated prosecution environment simplifies the management of the 1 pending office action, as there are no competing examiner styles to consider within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18038065 | PHARMACEUTICAL COMPOSITION COMPRISING INSOLUBLE CAMPTOTHECIN COMPOUND-CONTAINING NANOPARTICLE FOR TREATMENT OF CANCER AND COMBINATION THERAPY THEREOF | WANG, CHANG YU | 41d |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18038065 | PHARMACEUTICAL COMPOSITION COMPRISING INSOLUBLE CAMPTOTHECIN COMPOUND-CONTAINING NANOPARTICLE FOR TREATMENT OF CANCER AND COMBINATION THERAPY THEREOF | WANG, CHANG YU | 1675 | §103 | Final Rejection | 41d | Pending | May 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSnbioscience Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Chang Yu Wang has the most, with 1 of Snbioscience Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.